Published in final edited form as:

Tetrahedron Lett. 2015 July 1; 56(27): 4109–4111. doi:10.1016/j.tetlet.2015.05.029.

Synthesis of *N*-substituted aryl amidines by strong base activation of amines

Muhammad M. Khalifa^a, Micah J. Bodner^a, J. Andrew Berglund^{a,b}, and Michael M. Haley^{a,*}

^aDepartment of Chemistry & Biochemistry, University of Oregon, Eugene, OR 97403-1253, USA

^bInstitute of Molecular Biology, University of Oregon, Eugene, OR 97403, USA

Abstract

We describe an efficient method for the direct preparation of *N*-substituted aryl amidines from nitriles and primary amines. The protocol employs activation of amines by a strong base and provides greater access to a pharmaceutically relevant functional group. This synthetic approach tolerates deactivated nitriles, nitriles with competing substitution sites, and aryl amines.

Graphical abstract

Keywords

Amidine; amine; nitrile; base-activation; strong base

Introduction

Amidines are a class of pharmaceutically relevant small molecules, in addition to being important building blocks for organic chemical synthesis and having a number of applications in materials chemistry.^{1–13} Benzamidine, the simplest aryl amidine, is a competitive, specific inhibitor of trypsin. Its derivatives act as antimicrobial and antiparasitic agents and have been used for the treatment of a variety of diseases, including pneumocystis pneumonia, antimonyresistant leishmaniasis, and human African trypanosomiasis.^{14–20} Amidines are known to bind nucleic acids; such action is crucial to their mechanism of action in some disease models.^{21–24} This property has been known for some time, and

© 2015 Published by Elsevier Ltd.

*Corresponding author. Tel.: +1 541 346 0456; fax: +1 541 346 0487., haley@uoregon.edu (M.M. Haley).

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Supplementary data

Supplementary data (experimental procedures, characterization data and copies of ¹H and ¹³C NMR spectra of all amidines) associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.tetlet.201x.xxxx>.

modulation of long, amidine-containing compounds has been proposed for sequence-specific targeting of both RNA and DNA.²⁵ In addition to being evaluated for anti-inflammatory, analgesic, and anti-cancer properties, amidine-containing moieties continue to be important in the search for treatments against Alzheimer's disease, malaria, and myotonic dystrophy type 1 (DM1).^{16,26–31}

Recently, investigations of pentamidine (**1**, Figure 1) and related analogs revealed that *N*-substituted aryl bis-amidines may be especially relevant to the development of effective therapeutics against myotonic dystrophy type 1, as a recent study identified the triaminotriazinecontaining bis-amidine derivative **2** as a lead.^{22,31} These findings, in conjunction with preceding literature on amidines, point to the importance of *N*-substituted amidines in pharmaceutical chemistry.

Several amidine-containing moieties possess important pharmaceutical properties in their own right. Tetrahydropyrimidine derivatives (e.g., **3**) display specific m1 receptor agonist activity and can act as neuromuscular blocking agents.^{27,32–33} Benzimidazole derivatives have been investigated for their anthelmintic and antifungal activity; a new class of benzimidazole derivatives (e.g., **4**) has been identified as antimalarial lead compounds.^{29,34–36} Both motifs can be considered *N*-substituted amidines. This pharmaceutical salience is the impetus for studying new examples of *N*-substituted amidines and examining methods for amidine synthesis.

Creation of new *N*-substituted amidines for study necessitates functionalization of the amidine group. Direct addition of nitriles and amines to form amidines is not possible; several strategies have been described to overcome this synthetic obstacle.^{37–44} All possess limitations for use in *N*-substituted amidine synthesis, including poor synthetic efficiency, time and material economy, or starting material compatibility. Methods employing transition elements or metals have an added disadvantage when considering environmental impact.^{40–42}

Preparation of unsubstituted amidines under basic conditions has been described, but the approach is not well studied.^{16,45–46} Creation of a nucleophile by strong base activation of an amine presents the possibility of preparing a wider range of *N*-substituted amidines in less synthetic steps and without the use of transition elements or metals. Khanna et al. reported the use of strong bases to activate an aniline derivative;⁴⁷ however, the method's compatibility with a range of starting materials, chemoselectivity, and synthetic efficiency are in general not well known. Here, we outline a simple protocol for preparing *N*-substituted aryl amidines under basic conditions and use it to synthesize a series of representative amidine targets in an effort to delineate these important properties. We further demonstrate that bisamidines and larger, amidine-containing moieties such as tetrahydropyrimidines and benzimidazoles are accessible via this method.

Results and discussion

Molecules were chosen to demonstrate the feasibility of creating a functionalized amidine group that can be incorporated into the synthesis of pharmaceutically-relevant, amidine-

containing moieties. To this end, the first series of targets examined amidine accessibility using a range of amines and nitriles (Table 1). At room temperature, primary amines (**5a-d**) were deprotonated with *n*-BuLi before addition of benzonitrile (**6d**); subsequent acidic work up and column purification afforded the desired amidines (**7a-d**) in good yield (60–80%) as their HCl salts. This approach was conducive to amidine preparation even with less reactive aryl amines (**5a-b**). Yields via this method exceeded those typical of the Pinner synthesis, and even some methods utilizing transition elements or metal catalysis. Mono-substituted aryl amidines (**7a-h**) are readily accessible, further overcoming limitations of synthesis via transition elements and/or metals.^{40–41}

Under the same conditions, a series of aryl nitriles (**6e-h**) were added to the anion of 3-phenylpropylamine (**5e**). The products (**7e-h**) were obtained in substantive yield (40–60%), with deactivated nitriles (**6e-f**) giving comparable amounts of amidine to activated nitriles (**6g-h**). Though these yields are not markedly better than other established routes of preparation via acidic conditions, the array of compatibility with nitriles is noteworthy. Additionally, amidine formation by this method proceeds readily despite the presence of a competing nucleophilic aromatic substitution site on the nitrile (entry **g**). Mono-substituted amidines (**7e-h**) remain readily accessible, a feature of our protocol that overcomes limitations of amidine synthesis via lanthanide (III) triflates.^{40–41}

Having explored the use of primary monoamines and mono-amidine formation using a primary diamine, we sought to apply this protocol to the creation of bis-amidines. For this purpose, we examined a series of diamines as substrates and generated the corresponding amidines, including one with a core reminiscent of the pharmaceutically-relevant structure (**2**) described by Wong et al. (Table 2).³¹

Serial amidine formation is possible via the method described, as two rounds of deprotonation and subsequent benzonitrile addition give the respective bis-amidine for both alkyl and aryl amines. The use of 1,4-phenylenediamine (**8a**) affords the para-bis-amidine (**9a**) in high yield (87%); however, use of 1,2-phenylenediamine yielded a mixture of the desired bis-amidine **9c** and minor amounts of benzimidazole derivative **9e**, likely through the transamination mechanism described by Gupta et al.⁴⁸ Analogously, use of 1,3-diaminopropane (**8d**) yielded the desired bisamidine **9d** in addition to the cyclic tetrahydropyrimidine product **9f**. Both **9e** and **9f** could be prepared preferentially by omission of the second addition of PhCN. The yield via our method for such cyclic species is comparable to several literature methods for access of the same species.^{29,34,36} Thus large, cyclic, amidine-containing moieties remain synthetically accessible by our protocol, which also provides sufficient control over bis-amidine formation to allow for asymmetric synthesis where desired (albeit with less efficiency in cases where intramolecular transamination occurs readily).

Conclusion

The salience of *N*-substituted amidines to pharmaceutical chemistry is well established, and their synthetic accessibility continues to be relevant to the search for cures against a large number of human diseases. This project describes and studies a simple approach to the

preparation of *N*-substituted amidines as an alternative to methods utilizing nitrile activation by acidic conditions or electron withdrawal, transition elements, and/or metals. Importantly, the vast majority of amidine targets in this study were obtained in yields greater than 40%, often much greater, using 1:1 ratios of starting materials and reaction times of 24 h at room temperature. Throughout the study, the method was compatible with a wider range of starting materials than typically allowed by other synthetic approaches, and permitted access to hitherto undescribed amidine species (**7d-h**, **9d**) as well as previously described but poorly characterized amidine species (**9a-c**).⁴⁹ This protocol of amidine preparation by strong base activation of amines, as well as further exploration of the complimentary Khanna method,⁴⁷ should make accessible a range of new *N*-substituted amidines for study against a variety of human diseases.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The project was supported by Award Number R01AR059833 from the National Institutes of Health (NIH). The authors acknowledge the Biomolecular Mass Spectrometry Core of the Environmental Health Sciences Core Center at Oregon State University, supported in part by Award Number P30ES000210 from the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH).

References and notes

1. Das BP, Boykin DW. *J. Med. Chem.* 1977; 20:531–536. [PubMed: 321783]
2. Charette AB, Grenon M. *Tetrahedron Lett.* 2000; 41:1677–1680.
3. Korbadi BL, Lee S-H. *Bull. Korean Chem. Soc.* 2013; 34:1266–1268.
4. Aly AA, Nour-El-Din AM. *ARKIVOC.* 2008:153–194.
5. Chavan NL, Naik NH, Nayak SK, Kusurkar RS. *ARKIVOC.* 2010:248–255.
6. Lanteri CA, Trumpower BL, Tidwell RR, Meshnick SR. *Antimicrob. Agents Chemother.* 2004; 48:3968–3974. [PubMed: 15388460]
7. Dabak K. *Turk. J. Chem.* 2002; 26:547–550.
8. Gentile RJ, Macdonald JE, Murray RJ, Shakespeare WC. Amidine derivatives with nitric oxide synthetase activities. 1995 at <<http://www.google.com/patents/WO1995005363A1>>.
9. McKnight LE, Raman EP, Bezawada P, Kudrimoti S, Wilder PT, Hartman KG, Godoy-Ruiz R, Toth EA, Coop A, MacKerell AD Jr. Weber DJ. *ACS Med. Chem. Lett.* 2012; 3:975–979. [PubMed: 23264854]
10. Auer F, Nelles G, Sellergren B. *Chem. Eur. J.* 2004; 10:3232–3240. [PubMed: 15224332]
11. Tian T, Chen X, Li H, Wang Y, Guo L, Jiang L. *Analyst.* 2013; 138:991–994. [PubMed: 23259156]
12. Lee I, Kim S, Kim S, Jang Y, Jang J. *ACS Appl. Mater. Interfaces.* 2014; 6:17151–17156. [PubMed: 25197957]
13. Sarova GH, Bokach NA, Fedorov AA, Berberan-Santos MN, Kukushkin VY, Haukka M, Fraústo da Silva JJR, Pombiero AJL. *Dalton Trans.* 2006:3798–3805. [PubMed: 16883406]
14. von der Saal W, Engh RA, Eichinger A, Gabriel B, Kucznierz R, Sauer J. *Arch. Pharm.* 1996; 329:73–82.
15. Krieger M, Kay L, Stroud R. *J. Mol. Biol.* 1974; 83:209–230. [PubMed: 4821871]
16. Ismail MA, Arafa RK, Brun R, Wenzler T, Miao Y, Wilson WD, Generaux C, Bridges A, Hall JE, Boykin DW. *J. Med. Chem.* 2006; 49:5324–5332. [PubMed: 16913722]

17. Steck EA, Kinnamon KE, Rane DS, Hanson WL. *Exp. Parasitol.* 1981; 52:404–413. [PubMed: 7032963]
18. Stephens CE, Patrick DA, Chen H, Tidwell RR, Boykin DW. *J. Label Compd. Radiopharm.* 2001; 44:197–208.
19. Bakunova SM, Bakunov SA, Patrick DA, Kumar EVKS, Ohemeng KA, Bridges AS, Wenzler T, Barszcz T, Kilgore SJ, Werbovetz KA, Brun R, Tidwell RR. *J. Med. Chem.* 2009; 52:2016–2035. [PubMed: 19267462]
20. Tidwell RR, Kilgore SJ, Geratz JD, Ohemeng KA, Cory M, Hall JE. *J. Med. Chem.* 1990; 33:1252–1257. [PubMed: 2319567]
21. Edwards KJ, Jenkins TJ, Neidle S. *Biochemistry.* 1992; 31:7104–7109. [PubMed: 1643044]
22. Coonrod LA, Nakamori M, Wang W, Carrell S, Hilton CL, Bodner MJ, Siboni R, Docter AG, Haley MM, Thornton CA, Berglund JA. *ACS Chem. Biol.* 2013; 8:2528–2537. [PubMed: 24028068]
23. Wilson WD, Nguyen B, Tanious FA, Mathis A, Hall JE, Stephens CE, Boykin DW. *Curr. Med. Chem. Anticancer Agents.* 2005; 5:389–408. [PubMed: 16101490]
24. Demeunynck, M.; Bailly, C.; Wilson, WD. *DNA and RNA Binders, From Small Molecules to Drugs.* John Wiley & Sons; Weinheim: 2006.
25. Dervan PB. *Science.* 1986; 232:464–471. [PubMed: 2421408]
26. Arya S, Kumar N, Roy P, Sondhi SM. *Eur. J. Med. Chem.* 2013; 59:7–14. [PubMed: 23202484]
27. Messer WS Jr. Abuh YF, Ryan K, Shepherd MA, Schroeder M, Abunada S, Sehgal R, El-Assadi AA. *Drug Dev. Res.* 1997; 40:171–184.
28. Warf MB, Nakamori M, Matthys CM, Thornton CA, Berglund JA. *Proc. Nat. Acad. Sci.* 2009; 106:18551–18556. [PubMed: 19822739]
29. Sreena K, Ratheesh R, Rachana M, Poornima M, Shyni C. *Hygeia.* 2009; 1:21–22.
30. Patil UD, Mahulikar PP. *International Scholarly Research Notices.* 2012:e963195.
31. Wong C-H, Nguyen L, Peh J, Luu LM, Sanchez JS, Richardson SL, Tuccinardi T, Tsoi H, Chan WY, Chan HYE, Baranger AM, Hergenrother PJ, Zimmerman SC. *J. Am. Chem. Soc.* 2014; 136:6355–6361. [PubMed: 24702247]
32. Messer WS Jr. Abuh YF, Liu Y, Periyasamy S, Ngur DO, Edgar MAN, El-Assadi AA, Sbeih, Dunbar PG, Roknich S, Rho T, Fang Z, Ojo B, Zhang H, Huzl JJ, Nagy PI. *J. Med. Chem.* 1997; 40:1230–1246. [PubMed: 9111297]
33. Brimblecombe RW, Hunt RR, Rickard RL, Taylor JV. *British J. Pharm.* 1969; 37:425–435.
34. Ramachandran S, Hameed PS, Srivastava A, Shanbhag G, Morayya S, Rautela N, Awasthy D, Kavanagh S, Bharath S, Reddy J, Panduga V, Prabhakar KR, Saralaya R, Nanduri R, Raichurkar A, Menasinakai S, Achar V, Jiménez-Díaz MB, Martínez MS, Angulo-Barturen I, Ferrer S, Sanz LM, Gamo FJ, Duffy S, Avery VM, Waterson D, Lee MCS, Coburn-Flynn O, Fidock DA, Iyer PS, Narayanan S, Hosagrahara V, Sambandamurthy VK. *J. Med. Chem.* 2014; 57:6642–6652. [PubMed: 25007124]
35. Sawant R, Kawade D. *Acta Pharmaceutica.* 2011; 61:353–361. [PubMed: 21945914]
36. Rathee PS, Dhankar R, Bhardwaj S, Gupta M, Kumar R. *J. App. Pharm. Sci.* 2011; 1:140–142.
37. Shriner RL, Neumann FW. *Chem. Rev.* 1944; 35:351–425.
38. Sandler, SR.; Karo, W. *Organic Functional Group Preparations.* Vol. 12-III. Academic Press; San Diego: 1989.
39. Lee HK, Ten LN, Pak CS. *Bull. Korean Chem. Soc.* 1998; 19:1148–1149.
40. Rousselet G, Capdevielle P, Maumy M. *Tetrahedron Lett.* 1993; 34:6395–6398.
41. Garigipati RS. *Tetrahedron Lett.* 1990; 31:1969–1972.
42. Geden JV, Pancholi AK, Shipman M. *J. Org. Chem.* 2013; 78:4158–4164. [PubMed: 23472583]
43. Beyzaei H, Aryan R, Keshtegar Z. *Adv. Chem.* 2014:e834641.
44. Lentzen G, Neuhaus T. Synthesis of cyclic amidines. 2013 at <<http://www.google.com/patents/US8598346>>.
45. Boeré RT, Oakley RT, Reed RW. *J. Organomet. Chem.* 1987; 331:161–167.
46. Sanger AR. *Inorg. Nuc. Chem. Lett.* 1973; 9:351–354.

47. Khanna IK, Yu Y, Huff RM, Weier RM, Xu X, Koszyk FJ, Collins PW, Cogburn JN, Isakson PC, Koboldt CM, Masferrer JL, Perkins WE, Seibert K, Veenhuizen AW, Yuan J, Yang D-C, Zhang YY. *J. Med. Chem.* 2000; 43:3168–3185. [PubMed: 10956225]
48. Gupta S, Agarwal PK, Kundu B. *Tetrahedron Lett.* 2010; 51:1887–1890.
49. Gautier JA, Miocque M, Fauran C, Cloarec AYL. *Bull. Soc. Chim. Fr.* 1970:200–206.

Figure 1.
Amidines and amidine-containing moieties continue to be pharmaceutically relevant in studies of DM1, Alzheimer's disease, and malaria.

Table 1

Amidines prepared directly via addition of nitriles to activated amines.

Entry	R ¹	R ²	Yield ^a
a	<i>p</i> -NH ₂ Ph	H	62%
b	Ph	H	69%
c	CH ₂ Ph	H	77%
d	(CH ₂) ₄ Ph	H	81%
e	(CH ₂) ₃ Ph	OMe	44%
f	(CH ₂) ₃ Ph	Me	52%
g	(CH ₂) ₃ Ph	F	58%
h	(CH ₂) ₃ Ph	CF ₃	50%

^a Isolated as the HCl salt.

Table 2

Bis-amidines and cyclic amidines are accessible via the same method

H_2NRNH_2		1. <i>n</i> BuLi 2. PhCN 3. <i>n</i> BuLi 4. PhCN	→	Amidine
8a-d		THF, RT		9a-f
Entry	R	Product 9	Yield	
a	<i>p</i> -C ₆ H ₄		87% ^a	
b	<i>m</i> -C ₆ H ₄		32% ^a	
c	<i>o</i> -C ₆ H ₄		34% ^a	
d	(CH ₂) ₃		50% ^a	
e	<i>o</i> -C ₆ H ₄		32% ^b	
f	(CH ₂) ₃		60% ^{a,b}	

^a Isolated as the HCl salt.^b Step 4 omitted.